Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study
| Autor: | Antonietta Pecoriello, Sara Scarduelli, Francesco Inglese, Martina Garuti, Fabio Speafico, Massimiliano Beccaria, Giulia Cervi, Giuseppe De Donno, Claudio Borghi, Giuseppe Lucchini, Graziana Francesca Greco, Cleante Scarduelli |
|---|---|
| Přispěvatelé: | Cleante Scarduelli, Francesco Inglese, Massimiliano Beccaria, Fabio Spreafico, Martina Garuti, Antonietta Pecoriello, Giulia Cervi, Graziana Greco, Sara Scarduelli, Giuseppe Lucchini , Giuseppe De Donno, Claudio Borghi |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty pulmonary embolism Coronavirus disease 2019 (COVID-19) venous thromboembolism lcsh:Medicine 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine Pulmonary angiography COVID-19 Pulmonary embolism thromboprophylaxis Medicine Humans In patient 030212 general & internal medicine Retrospective Studies business.industry SARS-CoV-2 lcsh:R respiratory failure Anticoagulants COVID-19 Retrospective cohort study enoxaparin medicine.disease Pulmonary embolism Pneumonia Respiratory failure Lower prevalence Cardiology and Cardiovascular Medicine business |
| Zdroj: | Monaldi Archives for Chest Disease (2021) |
| Popis: | Coronavirus disease (COVID-19) may predispose patients to pulmonary embolism (PE), despite standard thromboprophylaxis. Our retrospective study aimed to report the prevalence of PE in patients with COVID-19 and severe respiratory failure (SRF) treated with intermediate- to full-dose enoxaparin. We analyzed data from patients with COVID-19 pneumonia and SRF admitted to our Respiratory Intensive Care Unit (RICU) from February 27 to April 20, 2020. All patients received at least intermediate-dose enoxaparin (40 mg twice daily). Computed tomography pulmonary angiography (CTPA) was used to detect PE. Ninety-two patients with COVID-19 pneumonia and SRF were admitted to our RICU. Twenty-two patients underwent CTPA (24 %), 11 of whom had PEs (12%). We hypothesize that the enoxaparin treatment may be responsible for the lower prevalence of PE as compared to previous reports of similar patients, even if our report had several limitations, mainly the small sample size. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|